Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials

Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials Meeting Abstract

publication date

September 1, 2023

webpage

Web of Science

published in

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Journal

start page

AB156

end page

AB156

volume

89

issue

3